Consequently, AT1-receptor-blocking therapies are expected to interrupt the vicious circle of SCD-induced lipid load and AT1 receptor up-regulation during the pathogenesis of heart failure (Figure 14). This evidence concerns the gene AGTR1 and heart failure.